Neurocrine Biosciences to Join the 2024 Cantor Global Healthcare Conference
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate in the 2024 Cantor Global Healthcare Conference. It’s a chance for the company to highlight recent progress in biopharmaceuticals, share what’s next, and connect directly with investors and industry leaders.
Presentation Details
The conference will be held in New York. Neurocrine’s Chief Business Development and Strategy Officer and CEO-elect, Kyle Gano, will be joined by Chief Financial Officer, Matt Abernethy, and Vice President of Investor Relations, Todd Tushla. Together, they’ll walk through the company’s current priorities and outlook. The live presentation is scheduled for September 17, 2024, at 3:05 p.m. Eastern Time.
How to Watch the Live Webcast
You can stream the presentation from the Investors section of Neurocrine Biosciences’ website. If you miss the live event, a replay will be posted roughly one hour after the session ends and will remain available for about a month. That way, you can watch the discussion on your own schedule and still hear the key points.
About Neurocrine Biosciences
Neurocrine Biosciences is a biopharmaceutical company focused on improving the lives of people with neurological and neuropsychiatric conditions. The team aims at areas of high unmet need and develops treatments for disorders that have historically been under-addressed. Its portfolio includes FDA-approved medicines for conditions such as tardive dyskinesia and chorea associated with Huntington’s disease, among others, alongside a pipeline designed to address serious, chronic challenges patients face every day.
Mission and Values
For more than three decades, Neurocrine has applied deep neuroscience expertise to discover, develop, and deliver therapies that make a difference. Guided by the belief that “you deserve brave science,” the company strives to reduce the burden of debilitating ailments with thoughtfully designed, rigorously tested treatments. Several compounds are currently in mid- to late-phase clinical trials across its core therapeutic areas, reflecting a sustained commitment to innovation and patient care.
Looking Ahead and Engaging the Community
As Neurocrine expands its work in neurotherapeutics, it continues to listen to patients, caregivers, clinicians, and advocacy communities. That feedback informs development priorities and helps shape programs that meet real needs. The result is a pipeline strengthened by lived experience and a clearer path to therapies that can be used in everyday care.
Stay Connected
For updates on products, programs, and company news, visit Neurocrine Biosciences’ website. You can also follow the company on social platforms, including LinkedIn, X (formerly Twitter), and Facebook, for ongoing insights and announcements.
Frequently Asked Questions
What is the 2024 Cantor Global Healthcare Conference?
It’s a gathering where healthcare companies share progress, strategy, and outlook with investors and industry peers, offering a closer look at near-term plans and long-term priorities.
Who will represent Neurocrine Biosciences at the conference?
Kyle Gano (Chief Business Development and Strategy Officer and CEO-elect), Matt Abernethy (Chief Financial Officer), and Todd Tushla (Vice President of Investor Relations) will present on behalf of the company.
When and where is Neurocrine’s presentation?
The live presentation will take place in New York on September 17, 2024, at 3:05 p.m. Eastern Time.
How do I watch the webcast and replay?
Go to the Investors section of Neurocrine Biosciences’ website to stream the live presentation. A replay will be posted about an hour after the session ends and will remain available for roughly a month.
What does Neurocrine Biosciences focus on?
The company develops treatments for neurological and neuropsychiatric disorders, including FDA-approved options for tardive dyskinesia and chorea related to Huntington’s disease, and continues to advance multiple mid- to late-stage clinical programs.
